Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma.
Fiche publication
Date publication
mars 2020
Journal
Gut
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BAUMERT Thomas, Dr DAVIDSON Irwin, Pr PESSAUX Patrick, Dr MUKHERJI Atish, Dr CROUCHET Emilie
Tous les auteurs :
Jühling F, Hamdane N, Crouchet E, Li S, El Saghire H, Mukherji A, Fujiwara N, Oudot MA, Thumann C, Saviano A, Roca Suarez AA, Goto K, Masia R, Sojoodi M, Arora G, Aikata H, Ono A, Tabrizian P, Schwartz M, Polyak SJ, Davidson I, Schmidl C, Bock C, Schuster C, Chayama K, Pessaux P, Tanabe KK, Hoshida Y, Zeisel MB, Duong FH, Fuchs BC, Baumert TF
Lien Pubmed
Résumé
Hepatocellular carcinoma (HCC) is the fastest-growing cause of cancer-related mortality with chronic viral hepatitis and non-alcoholic steatohepatitis (NASH) as major aetiologies. Treatment options for HCC are unsatisfactory and chemopreventive approaches are absent. Chronic hepatitis C (CHC) results in epigenetic alterations driving HCC risk and persisting following cure. Here, we aimed to investigate epigenetic modifications as targets for liver cancer chemoprevention.
Mots clés
chemoprevention, gene expression, hepatitis C, hepatocellular carcinoma, non-alcoholic steatohepatitis
Référence
Gut. 2020 Mar 26;: